These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
495 related articles for article (PubMed ID: 11398177)
1. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Dorai T; Cao YC; Dorai B; Buttyan R; Katz AE Prostate; 2001 Jun; 47(4):293-303. PubMed ID: 11398177 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Dorai T; Gehani N; Katz A Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300 [TBL] [Abstract][Full Text] [Related]
3. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208 [TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905 [TBL] [Abstract][Full Text] [Related]
5. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398. Fernández-Martínez AB; Bajo AM; Valdehita A; Isabel Arenas M; Sánchez-Chapado M; Carmena MJ; Prieto JC Peptides; 2009 Dec; 30(12):2357-64. PubMed ID: 19772879 [TBL] [Abstract][Full Text] [Related]
6. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Igawa T; Lin FF; Rao P; Lin MF Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Dorai T; Dutcher JP; Dempster DW; Wiernik PH Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424 [TBL] [Abstract][Full Text] [Related]
8. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076 [TBL] [Abstract][Full Text] [Related]
9. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271 [TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138 [TBL] [Abstract][Full Text] [Related]
11. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Chiu FL; Lin JK Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333 [TBL] [Abstract][Full Text] [Related]
12. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Samsel L; Zaidel G; Drumgoole HM; Jelovac D; Drachenberg C; Rhee JG; Brodie AM; Bielawska A; Smyth MJ Prostate; 2004 Mar; 58(4):382-93. PubMed ID: 14968439 [TBL] [Abstract][Full Text] [Related]
13. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104 [TBL] [Abstract][Full Text] [Related]
14. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551 [TBL] [Abstract][Full Text] [Related]
15. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Khor TO; Keum YS; Lin W; Kim JH; Hu R; Shen G; Xu C; Gopalakrishnan A; Reddy B; Zheng X; Conney AH; Kong AN Cancer Res; 2006 Jan; 66(2):613-21. PubMed ID: 16423986 [TBL] [Abstract][Full Text] [Related]
16. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo. Lee SC; Chan WK; Lee TW; Lam WH; Wang X; Chan TH; Wong YC Nutr Cancer; 2008; 60(4):483-91. PubMed ID: 18584482 [TBL] [Abstract][Full Text] [Related]
17. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Bandyopadhyay A; Wang L; López-Casillas F; Mendoza V; Yeh IT; Sun L Prostate; 2005 Apr; 63(1):81-90. PubMed ID: 15468171 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor. Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333 [TBL] [Abstract][Full Text] [Related]